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A key function of blood vessels, to supply oxygen, is
impaired in tumors because of abnormalities in their
endothelial lining. PHD proteins serve as oxygen
sensors and may regulate oxygen delivery. We there-
fore studied the role of endothelial PHD2 in vessel
shaping by implanting tumors in PHD2+/ mice. Hap-
lodeficiency of PHD2 did not affect tumor vessel
density or lumen size, but normalized the endothelial
lining and vessel maturation. This resulted in
improved tumor perfusion and oxygenation and
inhibited tumor cell invasion, intravasation, and
metastasis. Haplodeficiency of PHD2 redirected the
specification of endothelial tip cells to a more quies-
cent cell type, lacking filopodia and arrayed in
a phalanx formation. This transition relied on HIF-
driven upregulation of (soluble) VEGFR-1 and VE-
cadherin. Thus, decreased activity of an oxygen
sensor in hypoxic conditions prompts endothelial
cells to readjust their shape and phenotype to restore
oxygen supply. Inhibition of PHD2 may offer alterna-
tive therapeutic opportunities for anticancer therapy.
INTRODUCTION
Numerous studies have examined how blood vessels branch,
but little is known about the morphogenesis of the endothelial
cell (EC) layer. Nonetheless, a malshaped endothelium in‘‘abnormalized’’ tumor vessels impairs perfusion and oxygena-
tion (Jain, 2005). The resultant hypoxia promotes invasion,
metastasis, and malignancy (Sullivan and Graham, 2007). Tumor
hypoxia, together with hypoperfusion and increased interstitial
pressure, impedes delivery and efficacy of anticancer drugs.
Vessel normalization has therefore gained interest as a thera-
peutic option to improve drug delivery and anticancer treatment
(Jain, 2005). Nonetheless, current antiangiogenic agents induce
tumor hypoxia by pruning vessels or forming hypoperfused
vessels, which can stimulate angiogenesis and limit their
success (Bergers and Hanahan, 2008).
Endothelial ‘‘tip cells’’ at the forefront of a sprouting vessel
navigate by extending filopodia; ‘‘stalk cells’’ trail behind and
elongate the branch (Gerhardt et al., 2003). Both cell types
have distinct molecular signatures. Much less is known about
the EC type in nongrowing, quiescent vessels that maintain
lumen patency and form a tightly aligned, orderly shaped EC
layer with a cobblestone appearance.
Since supply of oxygen is an ancestral function of vessels, we
hypothesized that vessels should have mechanisms to sense
and adapt to changes in oxygen supply and, hence, perfusion
in case of oxygen shortage. The oxygen-sensing prolyl hydroxy-
lase domain proteins (PHD1–3) target hypoxia-inducible tran-
scription factors (HIFs) for degradation (Kaelin and Ratcliffe,
2008). When oxygen tension drops, PHDs become less active,
upon which stabilized HIFs mount an adaptive response, such
as angiogenesis (Semenza, 2003). However, severe tumor
hypoxia causes excessive release of angiogenic cytokines
and, thereby, tumor vessel abnormalization (Jain, 2005).
The role of the oxygen sensors in angiogenesis has not
been extensively studied. Inhibition of PHDs and silencing orCell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc. 839
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Figure 1. Reduced Tumor Invasion and Metastasis in PHD2+/ Mice
(A and B) Immunoblot of PHDs in mouse embryonic fibroblasts (MEF) (A) and of HIFs in endothelial cells (EC) and fibroblasts (MEF) (B).
(C) Growth of LLC tumors (n = 8; p = 0.33).
(D and E) Panc02 tumors (yellow line) are more invasive and metastatic in WT than PHD2+/ mice, as evidenced by hemorrhagic ascites, metastatic nodules
(blue line), jaundiced liver, and liver metastases (arrowheads).
(F and G) Hematoxylin and eosin (H&E) staining showing infiltrative B16 tumor foci in WT mice ([F]; arrowheads) but encapsulated borders in PHD2+/ mice ([G];
dashed line).
(H) Reduced metastasis of LLC tumors in PHD2+/ mice (n = 8; p < 0.0001).
(I and J) H&E staining revealing fewer pulmonary metastatic LLC tumor nodules in PHD2+/ mice (arrowheads).
(K) Reduced metastasis of Panc02 tumor cells in PHD2+/ mice (n = 27; p = 0.0001).
(L and M) Macroscopic view showing more metastatic mesenteric lymph nodes (arrowheads) in WT (L) than PHD2+/ (M) mice.
Scale bars represent 50 mm in (F), (G), (I), and (J). Asterisks in (H) and (K) denote statistical significance. Error bars in (C), (H), and (K) show the standard error of the
mean (SEM); all subsequent error bars are defined similarly.inactivation of PHD2 after birth stimulate angiogenesis (Milkie-
wicz et al., 2004; Nangaku et al., 2007; Takeda et al., 2007; Wu
et al., 2008), while overexpression of PHD2 in immortalized ECs
suppresses proliferation via hydroxylation-independent mecha-
nisms (Takeda and Fong, 2007). It is, however, unknown whether
PHDs regulate EC morphogenesis, vessel normalization, or
oxygen delivery. Here, we studied the role of PHD2 in these
processes, using tumor vessel abnormalization as a model.
RESULTS
Generation of PHD2+/ Mice and Expression of PHD2
To study its biological role in vivo, we inactivated the PHD2
gene (Figure S1A available online). PHD2-deficient (PHD2/)
mice died at midgestation, while PHD2+/ mice were healthy840 Cell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc.and displayed normal angiogenesis (Table S1, Figure S2).
PHD2 was undetectable in PHD2/ embryos (Figures S1B
and S1C) and present at 50% of wild-type (WT) levels in
PHD2+/ mice and cells at various oxygen tensions (Figure 1A
and Figure S3A). As PHDs are HIF targets (Epstein et al.,
2001; Marxsen et al., 2004), PHD3 and, to a lesser extent,
PHD1 levels were upregulated in PHD2+/ conditions (Figure 1A
and Figure S3A). PHD2 becomes gradually less active in
hypoxia but still retains activity at low oxygen tensions (Epstein
et al., 2001). HIF-1a levels were indeed higher in PHD2+/ cells
at every, even low, oxygen tension (Figure 1B and Figure S3B);
HIF-2a levels were also upregulated, particularly in ECs
(Figure 1B). By resetting their oxygen-sensing curve, PHD2+/
cells act as if they continuously sense lower oxygen tensions,
as if they are (pre)-adapted to hypoxia.
To study the role of stromal PHD2 in tumors without confound-
ing effects of a role of PHD2 in malignant cells, we used chimeric
tumor models, by implanting, in PHD2+/ mice, various PHD2+/+
tumor cells: B16 melanoma, Panc02 pancreatic carcinoma, and
Lewis lung carcinoma (LLC) cells. In vitro, PHD2 was detectable
in all tumor lines, blood and lymphatic ECs, and fibroblasts
(Figures S3C–S3E). In vivo, tumor, endothelial and fibroblast
cells were PHD2 positive (Figures S3F–S3H). In PHD2+/ mice,
transcript levels of PHD2 and PHD3 were reduced in tumors
and ECs, freshly isolated from tumors, and immediately analyzed
without subculturing (Figures S3I and S3J; see below for inter-
pretation).
Tumors Grow Normally, but Metastasis Is Reduced
in PHD2+/ Mice
Ectopic B16 and LLC tumors, or orthotopic Panc02 tumors, grew
at a comparable rate in both genotypes (Figure 1C and Figure S4)
and had comparable tumor cell proliferation and apoptosis (data
not shown). Tumors in PHD2+/ mice appeared less ‘‘bloody’’
(Figures 1D and 1E). As HIFs promote metastasis, we expected
that tumors in PHD2+/ mice would metastasize aggressively.
However, in PHD2+/ mice, B16 tumors were encapsulated,
grew focally, did not infiltrate surrounding tissues (Figures 1F
and 1G), and metastasized less (percent of lung sections with
metastases: 23% ± 3% in WT versus 7% ± 4% in PHD2+/;
n = 6; p = 0.01). Also, LLC tumors grew noninvasively (data not
shown), while pulmonary metastasis was reduced by 94%
in PHD2+/ mice (Figures 1H–1J and Figures S5A–S5D). After
resection of the primary tumor, haplodeficiency of PHD2
offered a survival benefit because of the reduced metastasis
(Figure S5E).
Panc02 tumors in PHD2+/ mice grew as encapsulated
tumors, while tumors in WT mice invaded the stomach and
duodenum (Figures 1D and 1E). Histologically, 50% of WT but
none of PHD2+/ mice had tumors with infiltrative margins (data
not shown). Also, liver metastasis was reduced in PHD2+/mice:
75% of WT mice but only 38% of PHD2+/ mice had hepatic
nodules, with 3.5 ± 0.8 nodules per WT mouse, but only 0.7 ±
0.3 nodules per PHD2+/ mouse (n = 6; p = 0.01; Figures 1D
and 1E). Furthermore, out of eight mice per group, six WT mice
but only two PHD2+/ mice displayed gallbladder enlargement
and jaundice (Figures 1D and 1E). Moreover, lymphatic metas-
tasis was reduced by 60% in PHD2+/ mice (Figures 1K–1M).
For subsequent studies, we used the Panc02 model, as this
tumor grows and metastasizes aggressively.
PHD2 Haplodeficiency Impedes Intravasation
of Tumor Cells
To characterize the role of PHD2 in metastasis, we analyzed
tumor intravasation. Staining for the EC marker CD105 and the
epithelial marker pancytokeratin revealed that tumor cell intrava-
sation was reduced by 50% in PHD2+/mice (percent of vessels
with intravasated tumor cells: 48% ± 5.0% in WT versus 24% ±
0.8% in PHD2+/; n = 6; p < 0.001; Figures 2A and 2B). Implan-
tation of Panc02 cells, transduced with a GFP-expressing
lentiviral vector, confirmed these findings (data not shown).
PHD2 haplodeficiency also reduced the number of circulating
GFP+ tumor cells by 79% (Figure 2C). Instead, intravenous injec-tion of GFP+ B16 tumor cells did not impair hepatic or pulmonary
colonization in PHD2+/ mice, indicating that tumor cell lodging
and extravasation in distant organs were normal (data not
shown).
In addition, gene profiling revealed that tumors in PHD2+/
mice expressed reduced levels of prometastatic genes that
promote survival, epithelial-mesenchymal transition, or motility
of tumor cells, stimulate extracellular matrix degradation, or
reduce cohesion between tumor-tumor or tumor-stromal cells
(COX2, EGFR, HGFR, CXCR4, MMP2, MMP9, uPA, IGF1R,
LOX, and N-cadherin), while expression of E-cadherin, which
promotes tumor-tumor cell adhesion (Sullivan and Graham,
2007), was increased (Sullivan and Graham, 2007) (Figure 2D
and Figure S5F). Notably, expression of these genes is regulated
by hypoxia through HIFs (Semenza, 2003).
Improved Tumor Oxygenation in PHD2+/ Mice
Since hypoxia promotes tumor cell invasion and metastasis, we
analyzed tumor oxygenation. Staining for the hypoxia-marker
pimonidazole revealed a reduced hypoxic tumor area in
PHD2+/ mice (21% ± 7% in WT versus 7% ± 3% in PHD2+/
for B16 tumors; n = 6; p = 0.01; Figures 2E and 2F). Electron para-
magnetic resonance (EPR) oxymetry indicated that the oxygen
pressure in B16 tumors was 2-fold higher in PHD2+/ mice
(Figure 2G). In tumors in PHD2+/ mice, protein levels of
HIF-1a were 3-fold lower (Figure 2H); levels of the HIF-target
vascular endothelial growth factor (VEGF) were also reduced
(mg per 10 mg tumor tissue: 4 ± 0.5 in WT versus 2.7 ± 0.2 in
PHD2+/; n = 6; p < 0.05). Also, the necrotic tumor area was
decreased in PHD2+/ mice (35% ± 9% in WT versus 16% ±
4% in PHD2+/ for B16 tumors; n = 6, p = 0.006; Figures 2I
and 2J). Consistent with its hypoxia inducibility (Epstein et al.,
2001; Marxsen et al., 2004), PHD3 mRNA levels in PHD2+/
mice were downregulated in tumors and tumor ECs freshly iso-
lated from tumors and directly used for analysis (Figures S3I
and S3J). PHD2 transcripts were also reduced in tumors in
PHD2+/ mice, in part because of the PHD2 haplodeficiency of
stromal cells, but likely also because of oxygen-dependent
downregulation of PHD2 in tumor cells (Figure S3I). Similar
results were obtained with the Panc02 tumor model (data not
shown). Overall, tumors are better oxygenated in PHD2+/ mice.
Tumors in PHD2+/ Mice Show Reduced Glycolysis
Tumor cells generate ATP largely via glycolysis (Warburg effect),
allowing rapid growth. The acidic microenvironment, resulting
from the formation of lactate, promotes tumor invasion and
malignancy. Since glycolysis is enhanced in hypoxic conditions,
lactate levels are a measure of tumor metabolism and indirectly
of its oxygenation. B16 tumors in PHD2+/ mice had lower
lactate contents (Figure 2K) and expressed lower levels of the
HIF-1a targets Glut-1 and PFK, key regulators of glycolytic flux
(Figure 2L). Thus, tumors in PHD2+/ mice were less glycolytic
because of improved oxygenation. Similar results were
obtained for Panc02 tumors (data not shown).
Consistent with a reduced Warburg effect, tumors in PHD2+/
mice expressed lower levels of PDK4, which restricts entry
of glycolytic intermediates into the Krebs cycle (mRNA copies
per 103 mRNA copies b-actin: 1.60 ± 0.43 in WT versusCell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc. 841
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Figure 2. Tumor Intravasation and Oxygenation in PHD2+/ Mice
(A and B) Panc02 tumor sections stained for endothelial CD105 (red) and epithelial cytokeratin (green) revealing more intravasated tumor cells (arrowheads)
in a WT (A) than PHD2+/ mice (B).
(C) Reduced circulating GFP+ tumor cells in PHD2+/ mice (n = 5; p = 0.0005).
(D) RT-PCR revealing downregulation of prometastatic genes and upregulation of the anti-metastatic E-cadherin in Panc02 tumors in PHD2+/ mice (percent of
WT levels; n = 5–12; p < 0.05).
(E and F) Decreased staining for pimonidazole (red) in tumors in PHD2+/ mice.
(G) EPR oxymetry revealing increased tumor oxygenation in PHD2+/ mice (n = 10; p = 0.003).
(H) Immunoblot for HIF-1a and b-tubulin revealing reduced [HIF-1a/b-tubulin] ratio in tumors in PHD2+/ mice (n = 4; p = 0.007).
(I and J) H&E staining showing necrotic area (yellow line) in a tumor of a WT (I) but not PHD2+/ mouse (J). Arrows, blood lakes.
(K–M) Reduced Warburg effect in B16 tumors in PHD2+/ mice, shown by reduced lactate content (n = 6; p = 0.04) (K), transcripts of Glut-1 and PFK (percent of
WT levels; n = 5; p < 0.05) (L), and [NADH/NAD+] ratio (n = 4; p < 0.05) (M).
Scale bars represent 50 mm in (A), (B), (E), (F), (I), and (J). Asterisks in (C), (D), (G), (H), and (K)–(M) denote statistical significance.0.45 ± 0.14 in PHD2+/; n = 6-10; p = 0.03); similar findings were
obtained for PDK1 (data not shown). Moreover, analysis of NAD+
levels, a measure of the redox status, revealed that tumors in
PHD2+/ mice shifted from glycolytic to more oxidative metabo-
lism (mg NAD+ per g tumor: 5 ± 2 in WT versus 14 ± 2 in PHD2+/;
n = 4; p < 0.05); similar results were obtained when the [NADH/
NAD+] ratio was analyzed (Figure 2M). Overall, tumors in
PHD2+/ mice were better oxygenated and adapted to more
aerobic metabolism, as occurs in more benign tumors.
PHD2 Haplodeficiency Improves Vessel Function
and Maturation
We then investigated how haplodeficiency of PHD2 improved
tumor oxygenation. Hypoxia in tumors may result from an insuf-842 Cell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc.ficient number of patent vessels or from supernumerary nonper-
fused vessels (Thurston et al., 2007). We had expected that
reduced PHD2 levels, via upregulation of HIFs, would stimulate
vessel branching. However, CD31 staining revealed that tumor
vessel density and vessel area were comparable in both geno-
types, in all tumor models tested (Figures 3A and 3B and Figures
S6A–S6D). Similar results were obtained when analyzing tumor
lymphatics (Figures S6E–S6H). Also, there was no shift in tumor
vessel size (Figures S6I and S6J). However, tumor vessels ap-
peared more fragile in WT mice, as blood extravasated in tumors
in WT but not inPHD2+/mice (Figures 2I and 2J), explaining why
tumors in WT mice appeared more reddish (Figures 1D and 1E).
We therefore analyzed whether an improvement in vessel
function might explain the increased tumor oxygenation in
PHD2+/ mice. Use of fluorescent microspheres revealed that
perfusion of melanomas was 3-fold higher in PHD2+/ mice
(Figure 3C). Microscopic analysis confirmed that perfusion was
increased in PHD2+/ mice (lectin+ vessels per optical field:
5.2 ± 0.5 in WT versus 7.9 ± 0.1 in PHD2+/; n = 4; p = 0.003).
This genotypic difference was specific for tumor vessels, as
healthy tissues displayed comparable vessel area, density, and
perfusion in both genotypes (Figure S7).
When tumor vessels are leaky, extravasation of plasma
increases the interstitial pressure, inducing vessel collapse and
impeding perfusion (Jain, 2005). Upon injection of Texas Red-
conjugated dextran and fluorescein isothiocyanate (FITC)-conju-
gated lectin, extravasation of dextran was reduced in B16
tumors in PHD2+/ mice (leaky vessels, percent of total: 70% ±
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B C Figure 3. Improved Vessel Function and
Maturation in PHD2+/ Mice
(A and B) Tumor vessel density (A) and vessel area
(B) (n = 6; p = not significant).
(C) Improved tumor perfusion in PHD2+/ mice
(percent of renal perfusion; n = 10; p = 0.02).
(D) Reduced tumor vessel leakiness in PHD2+/
mice upon injection with Texas Red-conjugated
dextran (red) and FITC-conjugated lectin (green).
White arrowheads on merged images indicate
sites of leakage.
(E and F) Staining for CD31 (green) and aSMA (red)
revealing more pericyte-covered tumor vessels
(arrowheads) in PHD2+/ (F) than WT (E) mice.
(G and H) Staining for CD31 (green) and laminin
(LAM) (red) revealing yellow ‘‘mature CD31+
LAM+ vessels,’’ red ‘‘empty CD31– LAM+ sleeves’’
(white arrowheads), and green ‘‘naked CD31+
LAM– vessels’’ (blue arrowheads) in tumors in WT
mice (G); tumors in PHD2+/mice contain primarily
yellow ‘‘mature CD31+ LAM+ vessels’’ (H).
Scale bars represent 50 mm in (D), (G), and (H) and
100 mm in (E) and (F). The asterisk in (C) denotes
statistical significance.
11% in WT versus 23% ± 9% in PHD2+/;
n = 4; p = 0.02; Figure 3D). Similar findings
were obtained when Evans Blue was
injected (Figure S8A) or transendothelial
electrical resistance was measured
in vitro (data not shown). Leakage of fluo-
rescent dextran or Evans Blue in healthy
vessels was normal in PHD2+/ mice
(Figure S8). A tighter EC barrier may
contribute to the reduced tumor intrava-
sation and intratumoral bleeding in
PHD2+/ mice.
Coverage of ECs by mural cells renders
vessels more mature, tight, and stable
and reduces tumor cell intravasation
(Gerhardt and Semb, 2008). Double
staining for CD31 and the mural marker
a-smooth muscle actin (SMA) revealed
that more SMA+ cells covered tumor
vessels in PHD2+/ mice (pericytes per
optical field: 21.1 ± 2.0 in WT versus 31.5 ± 2.8 in PHD2+/;
n = 5; p = 0.016; Figures 3E and 3F). ECs in stable vessels are
quiescent and surrounded by a laminin (LAM)-positive basement
membrane. In contrast, tumor vessels are unstable and remodel
continuously; because of the hypermotility of tumor ECs, new
naked vessels without basement membrane are formed, while
existing vessels become denuded and regress. Hence, a fraction
of tumor vessels consists of ECs surrounded by a LAM+ base-
ment membrane (referred to as ‘‘LAM+ vessels’’), while another
fraction consists of naked ECs without LAM+ basement
membrane (‘‘naked LAM– vessels’’). Yet other tumor vessels
persist as ‘‘empty LAM+ sleeves,’’ i.e., LAM+ basement
membrane channels from which ECs egressed. Hence, staining
for CD31 and laminin revealed that, of all tumor vessels analyzedCell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc. 843
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Figure 4. Endothelial Cell Normalization in PHD2+/ Mice
(A and B) Whole-mount staining of thick tumor sections for CD31 (red) revealing similar three-dimensional architecture of tumor vasculature in WT (A) and
PHD2+/ (B) mice. The EC lining is discontinuous (blue arrowheads) with ECs protruding in the lumen and perivascular tumor area (white arrowheads), resulting
in a hazy, thick appearance of the vessel wall in WT mice (A) but a smooth, continuous, sharply demarcated endothelial lining in PHD2+/ mice (B).
(C–H) Scanning electron microscopy of tumor vessels: in WT mice (C–E), vessels are lined by a disorganized, discontinuous, pseudostratified EC layer (black
arrowhead in [C]) with ECs crawling over each other (yellow arrowheads in [D]) while forming gaps or being absent in other denuded areas (data not shown);
ECs protrude filopodia-like extensions in the lumen (white arrowhead in [C]), possess numerous fenestrations (blue arrowheads in [E]), and fail to form tight cellular
junctions but are separated by intercellular gaps (red arrowheads in [E]). By contrast, tumor vessels in PHD2+/ mice (F–H) are lined by a regular, orderly formed,
smoothly aligned, tightly apposed, single cobblestone monolayer of ‘‘phalanx’’ ECs (F andG), with few fenestrations and tight intercellular junctions (H).
(I) Reduced tumor EC proliferation in PHD2+/ mice (staining for BrdU and CD105; n = 5, p < 0.001).
(J) Reduced tumor EC apoptosis in PHD2+/ mice (staining for cleaved caspase-3 and CD105; n = 5, p < 0.001).
(K) Confocal microscopy of tumor vessels in whole-mount sections, stained for ZO-1 (green) and CD31 (red), showing long ZO-1+ tight junctions in PHD2+/ ECs
but a scattered, discontinuous pattern of short ZO-1+ tight junctions in WT cells.
Scale bars represent 25 mm in (A), (B), and (K). Asterisks in (I) and (J) denote statistical significance.in WT mice, 68% ± 4% were LAM+, 12% ± 2% were naked
LAM–, and the remaining 20% ± 3% were empty LAM+ sleeves
(n = 4; Figure 3G). By contrast, in PHD2+/ mice, up to 89% ±
2% of the vessels were LAM+, while only 4% ± 2% were naked
LAM– vessels, and 7% ± 1% were empty LAM+ sleeves (n = 4;
p < 0.0001; Figure 3H). Thus, even though tumors in PHD2+/
mice contained a similar number of vessels, vessels were more
mature and stable, which could explain improved perfusion.
PHD2 Haplodeficiency Induces ‘‘Endothelial
Normalization’’
Whole-mount staining of thick tumor sections for CD31 revealed
that the three-dimensional architecture of the tumor microvascu-844 Cell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc.lature was comparably complex in WT and PHD2+/ mice (Fig-
ures 4A and 4B). However, in WT mice, the EC wall of tumor
vessels was thick, disorganized, irregular, and often discontin-
uous, with holes (‘‘honeycomb’’ appearance), and had ECs
protruding in the lumen and perivascular stroma. In contrast, in
PHD2+/mice, the wall of tumor vessels was sharply demarcated
with clearly defined boundaries and branching points and ECs
forming a continuous smooth lining without protrusions, resulting
in a more regular external vessel shape (Figures 4A and 4B). Thus,
PHD2 haplodeficiency did not substantially change the overall
architecture of the vascular network but altered the EC lining.
Scanning electron microscopy revealed that tumor ECs in
WT mice exhibited signs of a hyperactive, nonquiescent
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Figure 5. Enhanced (s)Flt1 and VE-Cadherin levels in PHD2+/ Endothelial Cells
(A) RT-PCR analysis of angiogenic genes; bars represent the change in gene expression in PHD2+/ ECs (percent of WT levels; p < 0.01).
(B and C) Double staining for CD105 (red) and (s)Flt1 (green) revealing stronger Flt1 signal in tumor vessels in PHD2+/ (C) than WT (B) mice.
(D and E) Whole-mount staining for VE-cadherin (red) and CD31 (green) showing more and longer VE-cadherin+ EC junctions in tumor vessels in PHD2+/
(E) than WT (D) mice.
(F) RT-PCR analysis revealing elevated levels of mFlt1, sFlt1, and VE-cadherin (VEC) in tumor ECs of PHD2+/ mice (n = 4, p < 0.05).
Scale bars represent 50 mm in (B) and (C) and 25 mm in (D) and (E). Asterisks in (A) and (F) denote statistical significance.endothelium, with few signs of contact inhibition. ECs were
loosely connected and detached from each other, had intercel-
lular gaps, protruding filopodia-like extensions in the lumen,
and highly fenestrated and exposed irregular cell borders, and
were arranged as a pseudostratified multiple cell layer, thereby
partially obstructing the lumen (Figures 4C–4E). In contrast,
tumor vessels in PHD2+/ mice were lined by a regular, orderly
formed, single EC monolayer with cobblestone appearance
(resembling a ‘‘phalanx’’ of the Greek military formation), which
was continuous and tightly packed, with a normal polarity and
few fenestrations (Figures 4F–4H), as a quiescent endothelium
(Baluk et al., 2005; Jain, 2005). Tumor EC proliferation and
apoptosis were also reduced in PHD2+/ mice (Figures 4I and
4J). The genotypic differences in EC morphogenesis were not
detected in renal and hepatic endothelium (data not shown).
Molecular analysis revealed that the EC barrier was tighter.
Immunostaining for the tight junction marker ZO-1 (zona
occludens) revealed that ZO-1+ tight junctions in tumor vessels
extended over longer distances in PHD2+/ ECs in situ (3.98 ±
0.90 mm in WT versus 4.98 ± 0.91 mm in PHD2+/; n = 8; p <
0.0001; Figure 4K). Similar findings were obtained for claudin-5
(4.7 ± 0.2 mm in WT versus 5.5 ± 0.2 mm in PHD2+/; n = 6;
p = 0.003). By scanning electron microscopy, tumor vessels inWT mice had intravascular fibrin threads and clots, which can
impair perfusion. These features of increased coagulation, which
can impair perfusion, were much less prevalent in PHD2+/ mice
(Figures S9A and S9B). Tumor vessels contained fewer fibrin
(ogen)-immunoreactive deposits in PHD2+/ mice (fibrin+ area,
percent of tumor area: 2.8% ± 0.4% in WT versus 1.1% ± 0.4%
in PHD2+/; n = 6; p = 0.01; Figures S9C and S9D).
PHD2+/ Endothelial Cells Have a Distinct Phenotype
To characterize how PHD2 haplodeficiency regulates tumor EC
phenotypes, we analyzed in confluent ECs the expression of
a set of genes known to regulate EC morphogenesis. Of all
candidates analyzed, soluble VEGFR-1 (sFlt1), membrane-
anchored VEGFR-1 (mFlt1), and the junctional adherens mole-
cule VE-cadherin were upregulated in PHD2+/ cells (Figure 5A
and Figures S10A and S10B). Their transcript levels were also
higher in PHD2+/ ECs when cultured at 1% O2 (i.e., the oxygen
tension in tumors) (Figures S10C–S10E). Immunostaining and
RT-PCR of freshly isolated tumor ECs confirmed that (s)Flt1
and VE-cadherin were upregulated in tumor ECs in PHD2+/
mice (Figures 5B–4F and Figures S10F–S10H). VE-cadherin
was also more abundant in tumors inPHD2+/mice (Figure S10I).
Expression for other genes involved in the specification ofCell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc. 845
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Figure 6. In Vitro Characterization of PHD2+/ Endothelial Cells
(A and B) Reduced proliferation (A) and motility (B) of PHD2+/ ECs in response to VEGF (n = 6, p < 0.05).
(C) Lamellipodia formation in response to VEGF is impaired in PHD2+/ ECs (n = 100 cells, p < 0.05).
(D–G) Phalloidin staining revealing comparable actin cytoskeleton in WT (D) and PHD2+/ (E) ECs in baseline conditions and the formation of lamellipodia (arrow-
heads) in a WT (F) but not in a PHD2+/ (G) EC upon VEGF stimulation.
(H) TUNEL staining revealing reduced apoptosis of starved PHD2+/ ECs in response to VEGF (n = 6; p < 0.02).
(I and J) Silencing of HIF-2a inhibits the upregulation of sFlt1 (I) and VE-cadherin (J) expression in normoxic PHD2+/ ECs (n = 3; p < 0.05).
(K and L) Staining of HIF-2a revealing stronger immunoreactive signal (arrowheads) in tumor ECs in PHD2+/ (L) than WT (K) mice.
Scale bars represent 50 mm in (D) – (G) and 25 mm in (K) and (L). Asterisks in (A)–(C) and (H) denote significance relative to WT; asterisks in (I) and (J) denote signif-
icance relative to scramble RNAi.endothelial tip or stalk cells or angiogenesis was comparable
(Figure 5A). Interestingly, levels of RGS5, a gene counteracting
tumor vessel normalization (Hamzah et al., 2008), tended to be
reduced, while levels of eNOS and Robo4, which promote vessel
normalization (Jones et al., 2008; Kashiwagi et al., 2008), were
slightly higher in PHD2+/ ECs (Figure 5A). PHD2 haplodefi-
ciency did not upregulate sFlt1 in cancer-associated fibroblasts
(Figures S10J and S10K).
HIF-Driven Responses of PHD2+/ Endothelial Cells
We then studied the response to VEGF, since elevated levels of
VE-cadherin and (s)Flt1 are known to modulate this response
(Carmeliet et al., 1999; Grazia Lampugnani et al., 2003; Kappas
et al., 2008; Kearney et al., 2004) and VEGF inhibits vessel matu-
ration (Greenberg et al., 2008). Proliferation and motility of
PHD2+/ ECs were reduced upon VEGF stimulation (Figures 6A
and 6B). Also, WT cells formed extensive lamellipodia and
filopodia, with polarized reorganization of the actin cytoskeleton
(Figures 6C and 6F and Figures S11A, S11G, and S11H; Movie
S1), while PHD2+/ cells failed to do so (Figures 6C and 6G and846 Cell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc.Figures S11A, S11G, and S11I; Movie S2). This defect was
specific for VEGF, as the response to FGF-2 was normal in
PHD2+/ cells (Figures S11B–S11G). The corneal neovasculari-
zation response to FGF-2 was also preserved in PHD2+/ mice
(data not shown). Apoptosis, induced by serum deprivation,
was reduced in PHD2+/ ECs, slightly in baseline conditions,
and, more significantly, upon stimulation with VEGF (Figure 6H).
Overall, PHD2+/ ECs were less responsive to the mitogenic
and migratory activity of VEGF while being more sensitive to its
survival activity.
Furthermore, silencing in vitro the expression of HIF-1a or
HIF-2a by more than 80% (data not shown) showed that the up-
regulation of sFlt1 and VE-cadherin in PHD2+/ ECs was in-
hibited primarily by silencing HIF-2a in normoxic conditions
(Figures 6I and 6J), while silencing of HIF-1a also contributed
in hypoxic conditions, albeit at a lower level (data not shown).
Immunostaining revealed a stronger signal for HIF-2a in tumor
vessels in PHD2+/ mice (HIF-2a+ tumor vessels, percent of
vessels with lumen: 30% ± 6% in WT versus 49% ± 4% in
PHD2+/; n = 4; p = 0.04; Figures 6K and 6L).
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Figure 7. Phenotypic Characterization of PHD2Cre/+ Mice
(A–H) Phenotype of PHD2Cre/+ mice with endothelial PHD2 haplodeficiency (Cre/+) and PHD2lox/+ (lox/+) control littermates. Panc02 tumor weight (A), vessel
density (C), and microvascular architecture (D and E) are comparable, but metastasis (B) and hypoxia (F) are reduced in PHD2Cre/+ mice (n = 10; p < 0.05).
Whole-mount CD31 staining and scanning electron microscopy reveal that, in contrast to PHD2lox/+ mice (D and G), the tumor endothelial layer is normalized
in PHD2Cre/+ mice (E and H) (see Figures 4F–4H for comparison).
(I) Scheme of key EC phenotypes. In abnormalized tumor vessels in WT mice, hypermotile endothelial tip-like cells protrude filopodia in the lumen and perivas-
cular stroma, and abnormally shaped ECs (irregular cell border) form a pseudostratified, loosely attached layer, while other vessel areas become denuded
(asterisk). In more normalized tumor vessels in PHD2+/ mice, ECs shift to a phalanx-like phenotype (smooth, regular cell border) characterized by EC survival,
tightness, and quiescence, which improves tissue perfusion and oxygen delivery. For reasons of clarity and simplicity, not all phenotypic features (such as for
instance, coverage by mural cells) are depicted.
(J) PHD2 model. Left: hypoxic tumor cells induce endothelial abnormalization by release of VEGF and other abnormalization factors, which impairs perfusion and
causes hypoxia. Right: ECs counteract this abnormalization switch, in part through upregulation of (s)Flt1 and VE-cadherin, thereby improving vessel perfusion
and oxygenation. This pathway is more effective inPHD2+/mice because endothelialPHD2 haplodeficiency resets oxygen sensing and makes them better (pre)-
adapted to hypoxia.
(K) Scheme of the endothelial abnormalization switch. Left: In healthy tissues, the production of abnormalization factors (AbFs) by (nonendothelial) parenchymal
cells is in balance with the production of normalization factors (NorFs) by ECs, resulting in EC normalization. Middle: In tumors in WT mice, excess production of
tumor cell-derived AbFs over EC-derived NorFs tilts the balance in favor of EC abnormalization. Right: In tumors in PHD2+/ mice, haplodeficiency of PHD2 up-
regulates the production of NorFs by ECs, thereby counteracting EC abnormalization; the resultant improved oxygenation lowers the production of AbFs by tumor
cells, overall re-equilibrating the balance in favor of EC normalization.
Scale bars represent 50 mm in (F) and (G). Asterisks in (B) and (F) denote statistical significance.Endothelial Haplodeficiency of PHD2 Induces
Endothelial Normalization
To confirm the role of PHD2 in ECs in vivo, we generated condi-
tional PHD2 haplodeficient mice (PHD2Cre/+) lacking a single
PHD2 allele in ECs by intercrossing PHD2lox/+ mice with Tie2:Cre
mice. Analysis of PHD2Cre/+ mice revealed that EC haplodefi-
ciency of PHD2 sufficed to phenocopy the key findings in
PHD2+/ mice. Indeed, primary tumor growth was comparable,
but metastasis was reduced (Figures 7A and 7B), while tumorvessel density (Figure 7C), area (data not shown), and architec-
ture (Figures 7D and 7E) were comparable. However, tumors
were better oxygenated (Figure 7F), and tumor vessels showed
the cardinal morphological signs of EC normalization (Figures
7D, 7E, 7G, and 7H). Further, general PHD2 haplodeficiency
did not alter the accumulation of inflammatory cells and
cancer-associated fibroblasts (data not shown). These condi-
tional knockout studies do not rule out a possible role for leuko-
cyte or fibroblast PHD2 in tumor biology.Cell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc. 847
DISCUSSION
This study identifies a basic biological role for endothelial PHD2
in oxygen delivery by regulating vessel morphogenesis. Our data
suggest a model whereby a decrease in the activity of PHD2 in
ECs in hypoxia counteracts abnormalization of the EC layer.
This involves a shift from an endothelial tip to a distinct pheno-
type, referred to here as the ‘‘phalanx phenotype,’’ and relies in
part on HIF-mediated upregulation of (s)Flt1 and VE-cadherin.
EC normalization provides a feedback mechanism for vessels
to readjust their shape, not number, in order to optimize oxygen
supply when the latter is insufficient.
In healthy tissues, ‘‘productive’’ angiogenesis generates
perfused blood vessels and improves oxygenation. By contrast,
tumor angiogenesis is often ‘‘nonproductive’’ as vessel abnorm-
alization impairs oxygen supply (Jain, 2005). The importance of
vessel normalization for tumor growth and treatment is being
increasingly recognized, but its relevance for metastasis
remained unknown (Hamzah et al., 2008; Kashiwagi et al.,
2008; Stockmann et al., 2008; Winkler et al., 2004). PHD2 haplo-
deficiency promoted endothelial rather than vessel normalization
(Figure 7I). The resultant tightened endothelial barrier, improved
tumor oxygenation, and downregulation of metastatic genes can
explain why PHD2 haplodeficiency suppressed tumor invasion,
intravasation, and metastasis. Thus, a change in endothelial
shape, even without alterations in vessel numbers, sufficed to
induce a shift to reduced malignancy and metastasis.
Hypoxic cancer cells stimulate angiogenesis by upregulating
factors such as VEGF (Semenza, 2003); this response is
controlled by PHD2 (Lee et al., 2008). When released by tumor
cells in excess, these angiogenic factors turn into EC ‘‘abnorm-
alization factors’’ (AbFs), which induce nonproductive abnormal-
ized vessels. This may initiate a vicious self-sustaining cycle in
which EC abnormalization impairs tumor perfusion and aggra-
vates hypoxia, which will then upregulate AbFs in tumor cells
even more and, in turn, amplify EC abnormalization again.
PHD2+/ ECs counteract this process by reinstalling EC normal-
ization (or preventing its abnormalization altogether). Indeed,
they upregulate EC ‘‘normalization factors’’ (NorFs) such
as (s)Flt1 and VE-cadherin, which antagonize the activity of
AbFs. EC normalization in turn will increase tumor oxygenation,
and interrupt the vicious cycle of EC abnormalization, driven by
hypoxic tumor cells. Together, WT tumor cells induce vessel ab-
normalization and impair oxygen supply, while PHD2+/ ECs
counteract this process in a negative feedback and readjust
oxygen supply by promoting endothelial normalization. A reduc-
tion of PHD2 activity by hypoxia in WT ECs will also trigger the EC
normalization program, but less efficiently than haplodeficiency
of PHD2 (see below). This model is schematically illustrated in
Figures 7J and 7K.
The responses of endothelial and tumor cells to hypoxia are
tightly linked, since the activity of PHD2 coordinately changes
in function of the oxygen tension. Thus, when oxygen levels
drop (and decrease the activity of PHD2 in tumor and ECs), the
absolute levels of AbFs and NorFs will coordinately rise. Since
tumor cells produce more AbFs than ECs produce NorFs, their
relative balance likely even tilts over to more EC abnormalization
in severe hypoxic conditions. This may explain why hypoxic848 Cell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc.suppression of PHD2 in ECs in WT mice cannot overcome the
strong abnormalization response by tumor cells. By rendering
ECs better preadapted to hypoxia than tumor cells, haplodefi-
ciency of PHD2 re-equilibrates this balance in favor of the EC
normalization response; this indirectly affects tumor cells as
well, since, as a result of the improved oxygenation, tumor cells
will now also produce fewer AbFs (Figure 7K). This model there-
fore predicts that pharmacological inhibition of PHD2 specifically
in ECs may also induce vessel normalization. In physiological
conditions, the relative balance between EC abnormalization
and normalization is more in equilibrium (Figure 7K). Ongoing
studies suggest that PHD2 haplodeficiency also normalizes
vessels in other pathological conditions, suggesting that it has
a more general role than in cancer alone (M.M. and P.C., unpub-
lished data).
PHD2 haplodeficiency did not affect the number of tumor
vessels. This may seem paradoxical to the observation that the
migratory and mitogenic responses of PHD2+/ ECs to VEGF
are impaired. However, these impaired responses are balanced
off by an increased survival response to VEGF, while their
responsiveness to other molecules (such as FGF-2) is still
preserved. Also, an increased EC motility may not necessarily
generate more vessels. We speculate that hypermotile WT ECs
‘‘move around’’ and leave their resident position more often.
As a result, existing vessels become denuded and regress, while
new naked vessels are formed coincidently. When both
processes are in balance, tumor vessel density remains
unchanged. By contrast, PHD2+/ ECs are more sessile and,
once lining a vessel, ‘‘stay put,’’ thereby reducing nonproductive
remodeling of vessel regression and sprouting. Hence, by being
more ‘‘passive’’ and quiescent, PHD2+/ tumor vessels maintain
their numbers.
Upregulation of VE-cadherin is a likely mechanism underlying
EC normalization. Indeed, VE-cadherin inhibits EC proliferation
and apoptosis and tightens the barrier (Carmeliet et al., 1999;
Taddei et al., 2008). It also induces a ‘‘normalized, stabilized,
quiescent’’ EC phenotype indirectly by inhibiting proliferation
and promoting survival in response to VEGF (Carmeliet et al.,
1999; Grazia Lampugnani et al., 2003). The VEGF-trap sFlt1
also participates in fine-tuning EC normalization. Interestingly,
a pericellular gradient of sFlt1 improves vessel morphogenesis
more than mFlt1 (Kappas et al., 2008; Kearney et al., 2004). It
remains to be determined how PHD2 interacts with other
‘‘normalization’’ pathways, such as nitric oxide, Tie2, MMPs,
myeloid-derived VEGF, Rgs5, and PDGFR-b (Greenberg et al.,
2008; Hamzah et al., 2008; Kashiwagi et al., 2008; Stockmann
et al., 2008; Winkler et al., 2004).
Endothelial tip and stalk cells each have their own molecular
signature (Gerhardt et al., 2003; Hellstrom et al., 2007). Phalanx
cells might represent another type of ECs with a distinct identity:
unlike tip cells, they extend few filopodia and migrate poorly in
response to VEGF, form a tight barrier and vascular lumen, and
express elevated levels of (s)Flt1 and VE-cadherin. They
resemble stalk cells by depositing basement membrane and es-
tablishing junctions but differ by their increased quiescence and
reduced mitogenic response to VEGF. We speculate that these
three EC phenotypes should not be considered as nonoverlap-
ping identities, but, more likely, as belonging to a spectrum of
phenotypes, whereby tip and phalanx cells represent the
extreme examples of either the most navigatory or the most
sedentary, quiescent cell type. Possibly, even though some of
the genes are expressed by each of the three cell types, different
threshold levels or qualitative signaling properties may specify
each cell type.
Our data suggest that HIF-2a is involved in EC normalization.
Consistent herewith, reduction of HIF-2a impairs vessel morpho-
genesis (Peng et al., 2000) and induces aberrant vascular
networks (Yamashita et al., 2008). Also, HIF-2a binds to
hypoxia-responsive elements in the VE-cadherin and Flt1
promoter in ECs (Dutta et al., 2008; Le Bras et al., 2007). More-
over, since HIF-2a is relatively resistant to degradation at oxygen
levels that normally lead to degradation of HIF-1a (Lofstedt et al.,
2007), it may be relevant in maintaining vessel normalization in
better oxygenated (normalized) vessels. Nonetheless, given the
dynamically changing tumor oxygen microenvironment, we
cannot exclude that upregulation of HIF-1a may also contribute
to vessel normalization.
Implantation of fibroblasts, in which PHD2 expression was
completely silenced, stimulates angiogenesis in healthy WT
mice through release of angiogenic factors (Wu et al., 2008). In
another study, inducible broad-spectrum inactivation of PHD2
after birth (PHD2IND-KO) induced growth of supernumerary vessels
in healthy organs (Takeda et al., 2008; Takeda et al., 2007). It
remains unclear whether the vascular changes in PHD2IND-KO
mice are secondary to the high hematocrit levels, hyperviscosity,
thrombosis, and cardiac dysfunction or to elevated circulating
VEGF levels (Minamishima et al., 2008; Takeda et al., 2007). An
alternative explanation may relate to the hydroxylation-indepen-
dent activity of PHD2, but this effect has been only identified in
immortalized ECs so far (Takeda and Fong, 2007). Since only
complete PHD2 inactivation caused spontaneous vessel
changes, PHD2 controls vessel number versus morphogenesis
in a gene dosage-dependent manner.
Finally, our findings suggest possible medical implications. By
normalizing the tumor vasculature, endothelial haplodeficiency
of PHD2 may shift tumors to a less malignant, metastasizing
phenotype. As oxygenation levels determine responsiveness to
irradiation and chemotherapy, inhibition of PHD2 might improve
anticancer therapy (M.M. and P.C., unpublished data). PHD2
inhibitors may represent an unanticipated class of antivascular
agents that, in contrast to traditional antiangiogenic therapy,
regulate vessel shape but not size or number. As quiescent
vessels in healthy tissues are not affected in PHD2+/ mice,
inhibition of PHD2 selectively targets tumor vessels. Obviously,
before any conclusion that PHD2 inhibitors might be useful for
anticancer therapy is drawn, these findings should be confirmed
in spontaneous tumor models. Also, strategies to deliver such
compounds selectively to ECs should be explored, and the
consequences of inhibiting PHD2 in malignant cells will need
to be carefully analyzed, as silencing of PHD2 may evoke both
oncogenic and tumor-suppressor effects on tumor cells or upre-
gulate vessel abnormalization factors in tumor cells (Couvelard
et al., 2008; Lee et al., 2008; Wu et al., 2008). At this stage, our
studies provide insight in how oxygen sensors help to shape
the microvasculature for one of its most important functions,
i.e., supplying oxygen to cells.EXPERIMENTAL PROCEDURES
Syngeneic Tumor Models
Five hundred thousand B16F10.9 melanoma and 105 Lewis lung carcinoma cells
were injected subcutaneously into the right flank or foot pad, respectively. Tumor
volumes were measured every 2 days with a caliper with the formula: V = p 3
[d2 3 D] / 6, where d is the minor tumor axis and D is the major tumor axis.
One million Panc02 tumor cells were injected into the head of the pancreas;
tumors were weighed after 10 days. Circulating tumor cells were scored on
1 ml of peripheral blood upon red blood cell lysis.
Histology and Electron Microsopy
All methods for histology and immunostaining have been described (Fischer
et al., 2007). For scanning electron microscopy analysis, mice were perfused
with 2% paraformaldehyde (PFA) and 2.5% glutaraldehyde in 0.1 M Na-caco-
dylate buffer for 7 min. Organs were dissected, cross-sectioned, and fixed o/n
in the same solution. Samples were postfixed with 2% osmiumtetroxide and
dehydrated in a graded aceton series, critical-point dried (Balzers CPD 030),
mounted on stubs, and coated with gold (SPI-MODULE Sputter Coater, SPI
Supplies). Images were obtained with a scanning electron microscope
(JEOL JSM-6360) at 15 kV.
In Vitro Biological Assays
ECS were derived from lungs as described (Kuhlencordt et al., 2004). For the
proliferation and apoptosis assay, 53 105 ECs were seeded in gelatin-coated
24-well plate. Subconfluent cell layers were either not stimulated or were stim-
ulated with 50 ng/ml VEGF. Proliferation was assessed upon BrdU incorpora-
tion and staining with FITC-conjugated anti-BrdU. Apoptosis was assayed by
TUNEL staining. For the motility assay, confluent cell layers seeded on a fibro-
nectin-coated 35 mm tissue culture dish were scratched in the absence or
presence of VEGF or FGF-2 (50 ng/ml). Images were acquired for 6–14 hr
with an image taken every 15 min. Quantification of lamellipodia and filopodia
was performed as described (Kitamura et al., 2008).
Expression Analysis
The following antibodies were used: rabbit anti-PHD1 (P. Ratcliffe), rabbit anti-
PHD2 (P. Maxwell; Novus), rabbit anti-PHD3 (Novus), rabbit anti-HIF-1, rabbit
anti-HIF-2 (Novus), goat anti-VE-cadherin (R&D Systems), and rabbit anti-
b-tubulin or anti-b-actin (Abcam). sFlt1 was measured by immunoassays
(R&D Systems). Quantitative RT-PCR was performed as described (Fischer
et al., 2007). For Assay ID (Applied Biosystems) and sequence of primers
and probes, see Table S2.
Hypoxia Assessment and Tumor Perfusion
Tumor hypoxia and perfusion were analyzed as described (Fischer et al.,
2007). Vessel leakage was analyzed after intravenous coinjection of 0.25 mg
Texas Red-conjugated Dextran 70 kD (Molecular Probes) and 0.05 mg FITC-
labeled lectin (Lycopersicon esculentum; Vector Laboratories). Ten minutes
later, mice were perfused with saline and 2% PFA. Tumors were then
harvested and frozen in optimum cutting temperature compound.
Oxymetry, Lactate, and Redox Potential
Tumor oxygen tension (pO2) was measured through the use of charcoal
powder (100 mg; CX0670-1; EM Science) as the O2-sensitive probe and EPR
spectrometer (Magnetech). Lactate concentration and [NADH/NAD+] ratio
were measured as described (Pospisilik et al., 2007).
Statistics
Data represent mean ± SEM of representative experiments unless otherwise
stated. Statistical significance was calculated by t test or two-way ANOVA
where indicated (Prism v4.0b), with p<0.05 considered statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures,
11 figures, two tables, and two movies and can be found with this article online
at http://www.cell.com/supplemental/S0092-8674(09)00068-3.Cell 136, 839–851, March 6, 2009 ª2009 Elsevier Inc. 849
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